Signals
Early Lung Cancer Just Became a Biomarker Test of the System
New Phase III ELEVATE data published in NEJM show adjuvant ensartinib sharply reduced recurrence risk after resection in ALK-positive NSCLC. The science is clear. The access question is whether early-stage lung cancer pathways can test fast enough to use it.
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
India Turns AI Eye Screening Into Public-Health Infrastructure
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.